Clover Health Investments stock
CLOVNASDAQClover Health Investments, Corp., HealthcareISIN US18914F1030
51Score 51 out of 100, Neutral
Price and trend
89 / 100
Price history
+94% in one yearThe chart shows daily closes over 6 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 34% above it.
Since June 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 57).
The price is 9.8% below its 52-week high. Largest decline in 6 years: 97% (June 2021 to April 2024).
Chart figures for advanced users
- SMA 50$4.59
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$3.64
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)57
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$1.70
- The lowest closing price of the last twelve months.
- Resistance$5.41
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Clover Health Investments, Corp. belongs to the Medical (Healthcare Plans) industry (United States) and, with a market value of $2.59B, is number 11 of 12 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $1.92B (up 40.3% year on year) and a loss of $85.55M.
- For fiscal 2026, analysts expect on average revenue of $2.97B (up 54.5%) and adjusted earnings per share of $0.06.
Show more
- MEQIRI Score 51 out of 100 (Neutral): rank 366 of 702 in Healthcare, median 53.
- Our model puts fair value at $1.66, with the price 194% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 55.4% a year since 2020, Medical (Healthcare Plans) median 11.9%.Growth 70
- Earnings turn into cashFree cash flow above 500% of earnings over the last 12 months.
- Analysts expect strong earnings growthUp 42.3% a year through 2028 (estimates from 4 analysts).Growth 70
Weaknesses
- Above fair valuePrice 194% above the fair value of $1.66.Valuation 11
- DilutionShare count up 28% since 2020.Capital allocation 32
- Volatile share priceVolatility 59% a year over the last 12 months.Stability 65
Its standout strengths are technical analysis and momentum, while fundamentals and valuation hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 52 to 51.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- high price swings
- price up very strongly over the past year
Valuation
Valuation signal
Significantly overvaluedIn our model the price counts as cheap below $1.19 and expensive above $2.77 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $2.81 (cash-flow model) and $0.51 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $1.48, at 7.8% it would be $1.92.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (22.9).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 54.5% on the twelve months before. Up to 2021 the bars include businesses that were later spun off or sold. On a comparable basis, as restated in the SEC annual reports, revenue grew 55.4% a year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 18%, operating −4%, net −4%.
Debt & balance sheet
latest quarterNo financial debt is reported on the balance sheet.
Earnings
- Next earnings
- 25 Feb 2027in 104 days
- Last reported
- 4 Nov 2026EPS reported $0.01 (expected −$0.01)above expectations
Analyst estimates
- Earnings per share
- $0.06+0.4%
- Revenue
- $2.97B+0.7%
- Earnings per share
- $0.11+9.9%
- Revenue
- $3.65B+3.2%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +9.1%2026 guidance raised across all metrics: revenue of $2.92 billion to $3.0 billion, adjusted EBITDA of $70 million to $85 million, GAAP net income of $20 million to $35 million.
“We now expect average Medicare Advantage membership of 156,000 to 158,000 members, total revenue of $2.92 billion to $3 billion, consolidated gross profit of $525 million to $555 million, adjusted EBITDA of $70 million to $85 million, and GAAP net income of $20 million to $35 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 5 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 7 insiders sold, $7.95M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Soares KarenSale
20 Oct 2026, Chief Legal Officer
- Shares
- 19,275
- Price
- $4.66
- Value
- $89,822
- Reynoso Jamie L.Sale
19 Oct 2026, CEO, Medicare Advantage
- Shares
- 4,066
- Price
- $4.41
- Value
- $17,931
- Toy AndrewSale
15 Oct 2026, Chief Executive Officer
- Shares
- 62,176
- Price
- $4.68
- Value
- $290,984
Show 32 more
- Soares KarenSale
15 Oct 2026, Chief Legal Officer
- Shares
- 14,673
- Price
- $4.68
- Value
- $68,670
- Thornton Joseph ClaySale
15 Oct 2026, Interim CFO
- Shares
- 4,591
- Price
- $4.68
- Value
- $21,486
- Wai ConradSale
15 Oct 2026, CEO, Counterpart Health
- Shares
- 23,627
- Price
- $4.68
- Value
- $110,574
- Reynoso Jamie L.Sale
15 Oct 2026, CEO, Medicare Advantage
- Shares
- 18,273
- Price
- $4.68
- Value
- $85,518
- Reynoso Jamie L.Sale
7 Oct 2026, CEO, Medicare Advantage
- Shares
- 2,006
- Price
- $4.63
- Value
- $9,288
- Reynoso Jamie L.Sale
5 Oct 2026, CEO, Medicare Advantage
- Shares
- 8,750
- Price
- $4.42
- Value
- $38,675
- Toy AndrewSale
1 Oct 2026, Chief Executive Officer
- Shares
- 318,806
- Price
- $4.19
- Value
- $1.34M
- Reynoso Jamie L.Sale
17 Sept 2026, CEO, Medicare Advantage
- Shares
- 1,921
- Price
- $4.56
- Value
- $8,760
- Oldakowski Joseph FrankSale
16 Sept 2026, VP OF FINANCE AND CONTROLLER
- Shares
- 3,170
- Price
- $4.64
- Value
- $14,709
- Wai ConradSale
15 Sept 2026, CEO, Counterpart Health
- Shares
- 300,000
- Price
- $4.72
- Value
- $1.42M
- Soares KarenSale
15 Sept 2026, Chief Legal Officer
- Shares
- 6,846
- Price
- $4.78
- Value
- $32,724
- Reynoso Jamie L.Sale
15 Sept 2026, CEO, Medicare Advantage
- Shares
- 9,273
- Price
- $4.78
- Value
- $44,325
- Oldakowski Joseph FrankSale
14 Sept 2026, VP OF FINANCE AND CONTROLLER
- Shares
- 20,000
- Price
- $5.16
- Value
- $103,200
- Thornton Joseph ClaySale
17 Aug 2026, Interim CFO
- Shares
- 17,775
- Price
- $4.39
- Value
- $78,032
- Toy AndrewSale
10 Aug 2026, Chief Executive Officer
- Shares
- 87,798
- Price
- $4.65
- Value
- $408,261
- Soares KarenSale
20 Jul 2026, Chief Legal Officer
- Shares
- 51,700
- Price
- $4.51
- Value
- $233,167
- Reynoso Jamie L.Sale
17 Jul 2026, CEO, Medicare Advantage
- Shares
- 4,839
- Price
- $4.53
- Value
- $21,921
- Toy AndrewSale
15 Jul 2026, Chief Executive Officer
- Shares
- 62,711
- Price
- $4.67
- Value
- $292,860
- Wai ConradSale
15 Jul 2026, CEO, Counterpart Health
- Shares
- 24,215
- Price
- $4.67
- Value
- $113,084
- Reynoso Jamie L.Sale
15 Jul 2026, CEO, Medicare Advantage
- Shares
- 13,119
- Price
- $4.67
- Value
- $61,266
- Soares KarenSale
15 Jul 2026, Chief Legal Officer
- Shares
- 10,519
- Price
- $4.67
- Value
- $49,124
- Thornton Joseph ClaySale
15 Jul 2026, Interim CFO
- Shares
- 4,630
- Price
- $4.67
- Value
- $21,622
- Reynoso Jamie L.Sale
8 Jul 2026, CEO, Medicare Advantage
- Shares
- 2,384
- Price
- $4.68
- Value
- $11,157
- Reynoso Jamie L.Sale
6 Jul 2026, CEO, Medicare Advantage
- Shares
- 6,229
- Price
- $5.26
- Value
- $32,765
- Toy AndrewSale
1 Jul 2026, Chief Executive Officer
- Shares
- 313,476
- Price
- $5.32
- Value
- $1.67M
- Reynoso Jamie L.Sale
17 Jun 2026, CEO, Medicare Advantage
- Shares
- 2,360
- Price
- $4.78
- Value
- $11,281
- Oldakowski Joseph FrankSale
16 Jun 2026, VP OF FINANCE AND CONTROLLER
- Shares
- 12,102
- Price
- $4.86
- Value
- $58,816
- Soares KarenSale
15 Jun 2026, Chief Legal Officer
- Shares
- 4,681
- Price
- $4.61
- Value
- $21,579
- Reynoso Jamie L.Sale
15 Jun 2026, CEO, Medicare Advantage
- Shares
- 6,350
- Price
- $4.61
- Value
- $29,274
- Reynoso Jamie L.Sale
11 Jun 2026, CEO, Medicare Advantage
- Shares
- 7,289
- Price
- $4.91
- Value
- $35,789
- Wai ConradSale
28 May 2026, CEO, Counterpart Health
- Shares
- 220,426
- Price
- $3.99
- Value
- $879,500
- Edwards Carladenise ArmbristerSale
18 May 2026, Board
- Shares
- 67,160
- Price
- $3.42
- Value
- $229,687
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Clover Health Investments
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 51
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Healthcare Plans)
The next larger and next smaller companies by market value
- CignaCI $78.07B64
- HumanaHUM $53.29B63
- CenteneCNC $34.79B54
- Molina HealthcareMOH $10.95B50
- Oscar HealthOSCR $9.88B70
- BradsaudeSAUD3.SA $8.48B80
- ProgynyPGNY $2.69B79
- Alignment HealthcareALHC $1.57B41
ETFs that hold Clover Health Investments
Held by 11 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Ageing Population UCITS ETF2B77 | 0.18% | 0.40% | €813.42M |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.17% | 0.30% | €185.82M |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.07% | 0.30% | €4.28B |
Show 5 more
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.07% | 0.30% | €2.22B |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.02% | 0.45% | €1.54B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.02% | 0.30% | €964.08M |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.02% | 0.43% | €2.5B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.01% | 0.10% | €395.74M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 7 Nov 2026, previously Weak
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.